Business Description
Takeda Pharmaceutical Co Ltd
NAICS : 325412
SIC : 2834
ISIN : JP3463000004
Share Class Description:
HAM:TKD: Ordinary SharesCompare
Compare
Traded in other countries / regions
4502.JapanTAK.USA0A87.UKTKD.GermanyTKD.AustriaTAKP34.BrazilTAK.Mexico IPO Date
1997-10-20Description
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.18 | |||||
| Equity-to-Asset | 0.48 | |||||
| Debt-to-Equity | 0.73 | |||||
| Debt-to-EBITDA | 4.09 | |||||
| Interest Coverage | 3.36 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 1.11 | |||||
| Beneish M-Score | -2.74 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.9 | |||||
| 3-Year EBITDA Growth Rate | -5.3 | |||||
| 3-Year EPS without NRI Growth Rate | -8 | |||||
| 3-Year FCF Growth Rate | -32.8 | |||||
| 3-Year Book Growth Rate | 11.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 2.53 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.8 | |||||
| 9-Day RSI | 49.77 | |||||
| 14-Day RSI | 50.37 | |||||
| 6-1 Month Momentum % | 3.54 | |||||
| 12-1 Month Momentum % | -1.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.28 | |||||
| Quick Ratio | 0.77 | |||||
| Cash Ratio | 0.38 | |||||
| Days Inventory | 284.69 | |||||
| Days Sales Outstanding | 58.55 | |||||
| Days Payable | 99.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.55 | |||||
| Dividend Payout Ratio | 1.06 | |||||
| 3-Year Dividend Growth Rate | 1.5 | |||||
| Forward Dividend Yield % | 4.59 | |||||
| 5-Year Yield-on-Cost % | 4.7 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | -2.75 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 66.05 | |||||
| Operating Margin % | 10.46 | |||||
| Net Margin % | 6.38 | |||||
| FCF Margin % | 11.18 | |||||
| ROE % | 4.05 | |||||
| ROA % | 1.93 | |||||
| ROIC % | 3.64 | |||||
| ROC (Joel Greenblatt) % | 19.39 | |||||
| ROCE % | 3.25 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 22.63 | |||||
| Forward PE Ratio | 34.38 | |||||
| PE Ratio without NRI | 22.63 | |||||
| Shiller PE Ratio | 31.03 | |||||
| Price-to-Owner-Earnings | 14.58 | |||||
| PEG Ratio | 2.63 | |||||
| PS Ratio | 1.45 | |||||
| PB Ratio | 0.94 | |||||
| Price-to-Free-Cash-Flow | 13.09 | |||||
| Price-to-Operating-Cash-Flow | 7.52 | |||||
| EV-to-EBIT | 25.95 | |||||
| EV-to-Forward-EBIT | 24.88 | |||||
| EV-to-EBITDA | 8.64 | |||||
| EV-to-Forward-EBITDA | 9.73 | |||||
| EV-to-Revenue | 2.35 | |||||
| EV-to-Forward-Revenue | 2.4 | |||||
| EV-to-FCF | 21.15 | |||||
| Price-to-Projected-FCF | 0.58 | |||||
| Price-to-Median-PS-Value | 0.77 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.26 | |||||
| Earnings Yield (Greenblatt) % | 3.85 | |||||
| FCF Yield % | 7.73 | |||||
| Forward Rate of Return (Yacktman) % | 18.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Takeda Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 28,051.357 | ||
| EPS (TTM) (€) | 1.127 | ||
| Beta | 0.13 | ||
| Volatility % | 11.59 | ||
| 14-Day RSI | 50.37 | ||
| 14-Day ATR (€) | 0.244157 | ||
| 20-Day SMA (€) | 25.5935 | ||
| 12-1 Month Momentum % | -1.62 | ||
| 52-Week Range (€) | 23.36 - 27.31 | ||
| Shares Outstanding (Mil) | 1,585.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Takeda Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Takeda Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Takeda Pharmaceutical Co Ltd Frequently Asked Questions
What is Takeda Pharmaceutical Co Ltd(HAM:TKD)'s stock price today?
The current price of HAM:TKD is €25.65. The 52 week high of HAM:TKD is €27.31 and 52 week low is €23.36.
When is next earnings date of Takeda Pharmaceutical Co Ltd(HAM:TKD)?
The next earnings date of Takeda Pharmaceutical Co Ltd(HAM:TKD) is 2025-01-31 Est..
Does Takeda Pharmaceutical Co Ltd(HAM:TKD) pay dividends? If so, how much?
The Dividend Yield %  of Takeda Pharmaceutical Co Ltd(HAM:TKD) is 4.55% (As of Today), Highest Dividend Payout Ratio of Takeda Pharmaceutical Co Ltd(HAM:TKD) was 1.98. The lowest was 0.75. And the median was 1.2. The  Forward Dividend Yield % of Takeda Pharmaceutical Co Ltd(HAM:TKD) is 4.59%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers